What genetic markers affect the efficacy of temozolomide in the treatment of glioblastoma multiforme?

The efficacy of temozolomide for glioblastoma multiforme is mainly influenced by MGMT promoter methylation, with additional modulation by TERT mutations. Evidence for other markers like ABCB1 polymorphisms and xCT/SLC7A11 expression is less established and warrants further investigation.

Authors

Tripdatabase

Publication Details

Journal: Zenodo (CERN European Organization for Nuclear Research)
Published: 2026-10-31
DOI: https://doi.org/10.5281/zenodo.23827434
Primary Topic: Glioma Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

What genetic markers affect the efficacy of temozolomide in the treatment of glioblastoma multiforme?

Tripdatabase

Oct 31, 2026

Zenodo (CERN European Organization for Nuclear Research)

Glioma Diagnosis and Treatment

article

What genetic markers affect the efficacy of temozolomide in the treatment of glioblastoma multiforme?

Tripdatabase

October 31, 2026article en

Abstract

Zenodo (CERN European Organization for Nuclear Research)

Openalex Percentile: Top 12%

Glioma Diagnosis and Treatment

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon

What genetic markers affect the efficacy of temozolomide in the treatment of glioblastoma multiforme? — Tripdatabase · Zenodo (CERN European Organization for Nuclear Research) (2026) | TGRS Research Map | TGRS